Farid Takes Helm of Aurion MAB - Summary - MDSpire

Farid Takes Helm of Aurion MAB

Aurion Biotech names Marjan Farid chair of medical advisory board

  • March 27, 2026

  • 2 min

Share

Objective:

To announce the appointment of Marjan Farid as chair of Aurion Biotech's medical advisory board.

Key Findings:
  • Farid is recognized for her contributions to corneal and ocular surface disease.
  • Aurion's AURN001 aims to address progressive vision loss from corneal endothelial disease.
  • The company has launched Vyznova, the first commercially available cell therapy for corneal endothelial disease.
Interpretation:

Farid's expertise is expected to enhance Aurion's strategic initiatives and clinical advancements in regenerative therapies.

Limitations:
  • The article does not provide detailed information on the specific roles and responsibilities Farid will undertake.
  • No data on the outcomes of AURN001's Phase 3 trials is included.
Conclusion:

Farid's leadership is anticipated to significantly influence the development of innovative treatments for corneal diseases.

Original Source(s)

Farid Takes Helm of Aurion MAB

  • March 27, 2026

Related Content

The Rise of Intelligent Ortho-K

Integrating EyeCare

As demand for ophthalmic services surges, EyeCare Partners is building a physician-led network designed to meet rising clinical and research needs

  • April 20, 2026

  • 10 min
Why Smart Eye Surgeons Still Make Bad Growth Decisions

You’re not making poor decisions; you’re being forced to decide without clear, trustworthy data across your patient journey